Results 1 to 10 of about 640,629 (321)

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1

Frontiers in Pharmacology, 2022
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, driven by the BCR-ABL1 fusion oncoprotein. The discovery of orthosteric BCR-ABL1 tyrosine kinase inhibitors (TKIs) targeting its active ATP-binding pocket, such as first-generation Imatinib
Hao Zhang, Hao Zhang, Mingsheng Zhu, Mingzi Li, Duan Ni, Yuanhao Wang, Liping Deng, Kui Du, Shaoyong Lu, Hui Shi, Chen Cai   +10 more
doaj   +2 more sources

Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review) [PDF]

International Journal of Oncology, 2016
Multiple myeloma (MM) is a mature B cell neoplasm that results in multi-organ failure. The median age of onset, diverse clinical manifestations, heterogeneous survival rate, clonal evolution, intrinsic and acquired drug resistance have impact on the ...
Bebawy, M, Brown, RD, Jaiswal, R, Krishnan, SR, Luk, F   +4 more
core   +2 more sources

Nude mice multi-drug resistance model of orthotopic transplantation of liver neoplasm and Tc-99m MIBI SPECT on p-glycoprotein

World Journal of Gastroenterology, 2005
To establish a model of drug-resistant neoplasms using a nude mice model, orthotopic transplantation of liver neoplasm and sporadic abdominal chemotherapy.Hepatocellular carcinoma cells HepG2 were cultured and injected subdermally to form the tumor-supplying mice.
Yu, Han, Xiao-Ping, Chen, Zhi-Yong, Huang, Hong, Zhu   +3 more
openaire   +3 more sources

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma

Frontiers in Oncology, 2023
Multiple Myeloma (MM) is an incurable neoplasm of mature B cells and the second most prevalent hematological malignancy worldwide. While combinations of proteasome inhibitors like bortezomib (Bz) and immunomodulators (IMiDs) like lenalinomide (Len) are ...
Antoine Domenger, Daniela Ricci, Véronique Mayau, Laleh Majlessi, Christophe Marcireau, Gilles Dadaglio, Caroline Demangel   +6 more
doaj   +2 more sources

Advances in Targeted Drug Resistance Associated with Dysregulation of Lipid Metabolism in Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma
Xiaoju Huang,1– 3 Mengmeng Wang,1– 3 Dan Zhang,1– 3 Chen Zhang,4 Pian Liu1– 3 1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China; 2Institute of Radiation ...
Huang X, Wang M, Zhang D, Zhang C, Liu P
doaj   +2 more sources

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia

Pharmaceutics, 2023
Chronic myeloid leukemia (CML) is a hematologic neoplasm characterized by the expression of the BCR::ABL1 oncoprotein, a constitutively active tyrosine kinase, resulting in uncontrolled growth and proliferation of cells in the myeloid lineage.
Noor E. Verhagen, Jan B. Koenderink, Nicole M. A. Blijlevens, Jeroen J. W. M. Janssen, Frans G. M. Russel   +4 more
doaj   +2 more sources

JAK2 46/1 (GGCC) Haplotype in Oncogenesis, as Risk Stratifier, and Indicator for Drug Resistance in Myeloproliferative Neoplasms. [PDF]

Int J Mol Sci
The JAK2 46/1 (“GGCC”) haplotype is an inherited genetic variation within the Jak2 gene locus that has become a focal point in research related to oncogenesis, particularly in myeloproliferative neoplasms (MPNs). We conducted a narrative review of landmark discoveries in hematological malignancies and Jak2, focusing on its role in oncogenesis, risk ...
Perrone M, Sergio S, Pranzo B, Tarantino A, Loglisci G, Matera R, Seripa D, Maffia M, Di Renzo N.   +8 more
europepmc   +2 more sources

A Bibliometric Analysis of Drug Resistance in Pediatric Acute Lymphoblastic Leukemia [PDF]

Advanced Biomedical Research
Background: Despite the improved outcomes in acute lymphoblastic leukemia (ALL), drug resistance remains a major challenge. This study provides the first overview of global research trends in pediatric ALL drug resistance, highlighting emerging ...
Alireza Khanahmad, Mohammad Hossein Khazaee-Nasirabadi, Mahshid Lotfi, Amir Hami   +3 more
doaj   +2 more sources

Kinome rewiring during acquired drug resistance in neuroendocrine neoplasms [PDF]

Endocrine-Related Cancer, 2021
Although there is evidence of a significant rise of neuroendocrine neoplasms (NENs) incidence, current treatments are largely insufficient due to somewhat poor knowledge of these tumours. Despite showing differentiated features, NENs exhibit therapeutic resistance to most common treatments, similar to other cancers in many instances.
Gerard, Corinne, Lagarde, Marie, Poizat, Flora, Oziel-Taieb, Sandrine, Garcia, Vincent, Roche, Catherine, Niccoli, Patricia, Barlier, Anne, Romano, David   +8 more
openaire   +3 more sources

Multi-Drug Resistance against Second-Line Medication and MicroRNA Plasma Level in Metastatic Breast Cancer Patients [PDF]

Iranian Journal of Medical Sciences, 2023
Background: Circulating microRNAs (miRNAs) can help to predict the chemotherapy response in breast cancer with promising results. The aim of the present study was to investigate the relationships between the miR-199a, miR-663a, and miR-663b expression ...
Mehdi Dehghani, Samira Mokhtari, Hassan Abidi, Behnam Alipoor, Mohammad Amin Nazer Mozaffari, Hossein Sadeghi, Reza Mahmoudi, Mohsen Nikseresht   +7 more
doaj   +1 more source